AU660662B2 - CD4-gamma2 and CD4-IgG2 chimeras - Google Patents

CD4-gamma2 and CD4-IgG2 chimeras Download PDF

Info

Publication number
AU660662B2
AU660662B2 AU14400/92A AU1440092A AU660662B2 AU 660662 B2 AU660662 B2 AU 660662B2 AU 14400/92 A AU14400/92 A AU 14400/92A AU 1440092 A AU1440092 A AU 1440092A AU 660662 B2 AU660662 B2 AU 660662B2
Authority
AU
Australia
Prior art keywords
chimeric
heavy chain
igg2
cell
gamma2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14400/92A
Other languages
English (en)
Other versions
AU1440092A (en
Inventor
Gary A Beaudry
Paul J. Maddon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of AU1440092A publication Critical patent/AU1440092A/en
Application granted granted Critical
Publication of AU660662B2 publication Critical patent/AU660662B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU14400/92A 1991-02-08 1992-02-10 CD4-gamma2 and CD4-IgG2 chimeras Ceased AU660662B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65368491A 1991-02-08 1991-02-08
US653684 1991-02-08
PCT/US1992/001143 WO1992013947A1 (fr) 1991-02-08 1992-02-10 CHIMERES DE CD4-GAMMA2 ET DE CD4-IgG2

Publications (2)

Publication Number Publication Date
AU1440092A AU1440092A (en) 1992-09-07
AU660662B2 true AU660662B2 (en) 1995-07-06

Family

ID=24621912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14400/92A Ceased AU660662B2 (en) 1991-02-08 1992-02-10 CD4-gamma2 and CD4-IgG2 chimeras

Country Status (10)

Country Link
US (2) US6451313B1 (fr)
EP (2) EP1340769B1 (fr)
JP (1) JP3670276B2 (fr)
AT (1) ATE288923T1 (fr)
AU (1) AU660662B2 (fr)
CA (1) CA2080226C (fr)
DE (1) DE69233480T2 (fr)
ES (1) ES2237727T3 (fr)
HK (1) HK1059789A1 (fr)
WO (1) WO1992013947A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
JP3670276B2 (ja) * 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド CD4― ガンマ・2キメラ及びCD4 ― IgG2・キメラ
CA2141673A1 (fr) 1992-08-07 1994-02-17 Graham P. Allaway Fraction non peptidique d'immunoconjugues cd4-gamma2 et cd4-igg2 et ses utilisations
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
WO1996002575A1 (fr) * 1994-07-13 1996-02-01 Progenics Pharmaceuticals, Inc. Articles manufactures permettant d'eliminer le vih-1 d'un echantillon, et procedes faisant appel a ces articles
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
CN103212084B (zh) * 2003-11-13 2018-07-13 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AU2005222641B2 (en) * 2004-03-15 2011-04-07 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
EP2025762A3 (fr) 2006-01-17 2009-09-30 Health Research Inc. Analyse de suivi hétéroduplex
US20080051503A1 (en) * 2006-08-28 2008-02-28 The Goodyear Tire & Rubber Company Method of mixing fiber loaded compounds using a Y-mix cycle
JP5563572B2 (ja) 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
WO2011076781A1 (fr) * 2009-12-22 2011-06-30 Novartis Ag Protéine hybride tétravalente à région constante d'anticorps anti-cd-47 à utiliser en thérapie
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2015187977A1 (fr) * 2014-06-04 2015-12-10 Acceleron Pharma, Inc. Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
WO2016154601A1 (fr) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Protéines de fusion associées à la follistatine et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3281889A (en) * 1988-01-22 1989-08-11 General Hospital Corporation, The Cloned genes encoding ig-cd4 fusion proteins and the use thereof
AU1423792A (en) * 1991-02-12 1992-09-07 Colorado State University Research Foundation Reagents and methods for identification of vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
DE3751751T2 (de) 1986-08-21 1996-10-17 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
JPH02501192A (ja) 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性t4蛋白を製造するためのdna配列、組換dna分子および方法
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
IL91070A (en) * 1988-07-23 1995-03-30 Us Commerce Cytotoxic agents against certain viral infections
JPH02107393A (ja) * 1988-10-18 1990-04-19 Asahi Chem Ind Co Ltd 排水中の塩素系溶剤の除去方法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
EP0739904A1 (fr) * 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
WO1992013559A1 (fr) * 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CHIMERES DE CD4-GAMMA1 ET DE CD4-IgG1
JP3670276B2 (ja) * 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド CD4― ガンマ・2キメラ及びCD4 ― IgG2・キメラ
CA2141673A1 (fr) * 1992-08-07 1994-02-17 Graham P. Allaway Fraction non peptidique d'immunoconjugues cd4-gamma2 et cd4-igg2 et ses utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3281889A (en) * 1988-01-22 1989-08-11 General Hospital Corporation, The Cloned genes encoding ig-cd4 fusion proteins and the use thereof
AU1423792A (en) * 1991-02-12 1992-09-07 Colorado State University Research Foundation Reagents and methods for identification of vaccines

Also Published As

Publication number Publication date
JP3670276B2 (ja) 2005-07-13
EP0528011A4 (en) 1993-06-30
EP1340769B1 (fr) 2005-02-09
HK1059789A1 (en) 2004-07-16
JPH05507854A (ja) 1993-11-11
CA2080226A1 (fr) 1992-08-09
EP0528011A1 (fr) 1993-02-24
ATE288923T1 (de) 2005-02-15
ES2237727T3 (es) 2005-08-01
EP1340769A1 (fr) 2003-09-03
AU1440092A (en) 1992-09-07
WO1992013947A1 (fr) 1992-08-20
DE69233480D1 (de) 2005-03-17
US6187748B1 (en) 2001-02-13
US6451313B1 (en) 2002-09-17
CA2080226C (fr) 2004-05-04
DE69233480T2 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
AU660662B2 (en) CD4-gamma2 and CD4-IgG2 chimeras
US6083478A (en) Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof
JP2980928B2 (ja) Ig‐cd4融合タンパク質をコードするクローン化された遺伝子及びそれらの用途
US6117656A (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
US6165745A (en) Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH05503009A (ja) リガンド結合タンパク質および安定血漿タンパク質からなる融合タンパク質
AU648041B2 (en) Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
WO1992013559A1 (fr) CHIMERES DE CD4-GAMMA1 ET DE CD4-IgG1
US7070991B2 (en) Cells expressing a CD4-IgG2 chimeric heterotetramer
IL91070A (en) Cytotoxic agents against certain viral infections
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
CA1340741C (fr) Genes clones codant des proteines de fusion ig-cd4 et leur emploi
US6342586B1 (en) Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
AU692751C (en) Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof
AU611551C (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
AU623924B2 (en) Cytotoxic agent against specific virus infection